Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Thursday, 31'st Jul 2025
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compa
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates
09:11am, Thursday, 31'st Jul 2025
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.07 per share a year ago.
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
07:01am, Thursday, 31'st Jul 2025
Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments O
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
06:59am, Thursday, 31'st Jul 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025.
Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs
05:59pm, Wednesday, 30'th Jul 2025
Nine of the top sixteen Barron's Better Bets 'Safer' dividend dogs are attractively priced, offering dividends from $1K invested exceeding their share price. Analyst projections suggest 18-29% net gai
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
10:15am, Wednesday, 30'th Jul 2025
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements c
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
09:35am, Wednesday, 30'th Jul 2025
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
04:20am, Wednesday, 30'th Jul 2025
Often, great investing boils down to holding on to great stocks. It can be as simple as that.
Bristol Myers, Bain Capital form new company to develop immunology drugs
05:59pm, Monday, 28'th Jul 2025
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the compan
Bristol Myers Squibb and Bain Capital Form New Immunology Company
05:05pm, Monday, 28'th Jul 2025
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.
PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical.
Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector
02:06pm, Monday, 28'th Jul 2025
Umer Raffat, Evercore ISI senior analyst, joins 'The Exchange' to discuss if there's a turnaround coming for the health care sector.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
11:31am, Monday, 28'th Jul 2025
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
10:31am, Monday, 28'th Jul 2025
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
06:59am, Friday, 25'th Jul 2025
PRINCETON, N.J.--(BUSINESS WIRE)--Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development.
